European Psychiatry - Volume 41 - April 2017

283 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302 S279
Objectives Heterogeneity on basis of the important sign jeopar-
dizes the signal detection.
Aims Assessment of interaction between clinical symptoms and
CD in schizophrenic patients in remission with and without resid-
ual psychotic symptoms (RPS).
Methods Adult schizophrenic patients in remission with and
without RPS (DSM 295.30) on stable treatment not less than 6
months were assessed with PANSS, CGI, BACS. The indices of the
testing were compared between groups. The correlation analy-
sis was performed. The correlation was considered significant if
R > 0.60.
Results Ten females and 34 males were divided into two groups
according to presence (27 patients) or absence (17 patients) of
RPS (PANSS items P1 and P3 > 2 but < 5). The severity of symp-
toms and CD were equal in both groups, excluding P6 (P = 0.0005),
P20 (P= 0.007), P23 (P = 0.0004), and positive subscale PANSS
(P = 0.00001). In the group without RPS, we found that CGI score,
scores of 10 items of PANSS, scores of PANSS subscales, excluding
negative subscale, and total PANSS score highly negatively corre-
lated with total BACS score (average R = –0.70 ±10). In the group of
patients with RPS, no correlations were found.
Conclusions Patients with RPS has clinical significant dissociation
of psychic and cognitive functioning that should be consid-
ered in planning, and assessing of results of cognitive enhancers
studies.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0508
The peculiarity of experiencing body
by patients in schizophrenia
G. Rupchev ∗ , A. Alekseev , A. Tkhostov , A. Spivakovskaya ,
V. Guldan
1 Federal State Budgetary Scientific Institution “Mental Health
Research Center”, Laboratory of Psychopharmacology, Moscow,
Russia
2 Lomonosov Moscow State University, Faculty of Psychology, Clinical
Psychology Department, Moscow, Russia
3 Lovonosov Moscow State University, Department of clinical
psychology, Moscow, Russia
∗ Corresponding author.
Introduction By the present, the study of corporeality as a psycho-
logical phenomenon in schizophrenia has had a lack of attention. At
the focus ofworks, there have beenmainly psychopathological phe-
nomena: cenestopathies, visceral hallucinations and body scheme
disturbances. There is an evidence of the necessity for psychologi-
cal investigations: the execution of radical changes in appearance,
a frequent turning to plastic surgery, dysfunctional wearing and
transsexuality.
Objectives The experimental group consisted of 23 patients in
schizophrenia of paranoid type (F 20.00). The control group con-
sisted of 27 healthy subjects.
Aim It is to study the peculiarity of experiencing their own body
by patients in schizophrenia.
Methods There are projective techniques, such as: “A Picture of
Me”, “Verbal Self-Portrait”, ‘A Picture of Inner Body” and the psy-
chosemantic test “Classification of Sensations”.
Results There are statistically significant differences (P < 0.005)
found between the groups:
– patients with schizophrenia are characterized for their deficit of
experiencing their body. It does not refer to “Myself” and is dein-
vidualized. The body does not serve as a physical presentation of
the subject in a social world;
– awary attitude is observed in relation to body displays in the form
of inner body sensations with a minor (than in norm) awareness
relatively to the inner arrangement of their own body. This causes
the increase of the quantity of intraceptive sensations categorized
by patients in schizophrenia as unhealthy or a threat.
Conclusion The above-mentioned peculiar features of corporeal-
ity in schizophrenia make it a source of negative experiences.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0509
Effectiveness of paliperidone
palmitate long-acting injectable in the
initial stages of psychosis: Clinical and
functional impact
L. Sánchez Blanco ∗, M. Gómez Revuelta , V. Gajardo Galán ,
M. Juncal Ruíz , R. Landera Rodríguez ,
G. Pardo de Santayana Jenaro , O. Porta Olivares ,
N.I. Nú˜nez Morales
1 Hospital Universitario Marqués de Valdecilla, Psychiatry,
Santander, Spain
2 Hospital Universitario de Álava-sede Santiago, Psychiatry,
Vitoria-Gasteiz, Spain
∗ Corresponding author.
Introduction An appropriate early intervention (EI) after the
onset of a first episode of psychosis (FEP) is a key factor to prevent
relapse, cognitive and functional impairment related to neurotox-
icity as it is a critical period in order to get good adherence to
treatment. This is the most reported factor linked to relapse. There-
fore, interventions focused on getting good adherence to treatment
may make the difference in terms of outcome.
Aims To compare relapse rates, symptom severity and level of
functionality before and after treatment with Paliperidone Palmi-
tate Long-Acting Injectable (PP-LAI). To analyze prior antipsychotic
treatments and side effects registered before and after the introduc-
tion of (PP-LAI).
Material and method This is a cross-sectional descriptive study.
We analyzed a sample of 15 patients, recruited from PAFIP (an spe-
cialized EI unit) and treated with variable doses of PP-LAI. They all
met diagnostic criteria for schizophrenia according toDSM-IV. Clin-
ical and functional data of the two years before and after treatment
intoroduction were recorded.
Results Twenty-seven percent of the patients resumed their
work activity or studies and 33% of the patients increased their
social activity. Thirteen percent of the patients improved from
negative symptoms. Prior to treatment introduction, more than a
half of the simple, had suffered one or two relapses. After treat-
ment introduction, 87% did not experiencemore relapses while 13%
experienced another relapse.
Conclusions Treatment with PP-LAI is associated to a recovery
of functional abilities, and a trend to clinical stability with high
adherence to treatment related to few side effects.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0510
Adjunctive memantine in
clozapine-treated refractory
schizophrenia: An open-label
one-year extension study
P. Schulte ∗, S. Veerman , J.B. Deijen , L. De Haan
1 Mental Health Service North-Holland-North, Department for
Specialized Treatments, Treatment Center for Bipolar Disorder,
Alkmaar, Netherlands
2 Mental Health Service North-Holland-North, Community Mental
Health Division, Alkmaar, Netherlands